Beta Bionics (BBNX) Preferred Stock Liabilities (2023 - 2024)
Beta Bionics recorded quarterly Preferred Stock Liabilities of $321.4 million in Q4 2024, up 22.8% quarter-over-quarter from $261.7 million in Q3 2024, and up 22.8% year-over-year from $261.7 million in Q1 2024.
Beta Bionics' Preferred Stock Liabilities history runs 2 years deep, the most recent figure standing at $321.4 million for Q4 2024.
- In Q4 2024, Preferred Stock Liabilities rose 22.8% year-over-year to $321.4 million; the TTM figure through Dec 2024 stood at $321.4 million (up 22.8% YoY), while the FY2024 annual figure was $321.4 million, up 22.8% from the prior year.
- Preferred Stock Liabilities came in at $321.4 million for Q4 2024 at Beta Bionics, up from $261.7 million in the prior quarter.
- In the past five years, Preferred Stock Liabilities ranged from a high of $321.4 million in Q4 2024 to a low of $261.7 million in Q4 2023.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn | - |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn | - |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn | - |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn | - |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn | - |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | - |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn | - |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn | - |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn | - |
| 10 | Beta Bionics | 572.34 Mn | 542.03 Mn | 16.44 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 321.37 Mn |
| Sep 30, 2024 | 261.71 Mn |
| Jun 30, 2024 | 261.71 Mn |
| Mar 31, 2024 | 261.71 Mn |
| Dec 31, 2023 | 261.71 Mn |